A Multi-center, Non-interventional Prospective Clinical Trial to Evaluate the Safety and Effectiveness of CVA-FLOW

Sponsor
Cvaid Medical (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT06101004
Collaborator
Donawa Lifescience Consulting (Other)
460
2
7.2
230
31.8

Study Details

Study Description

Brief Summary

CVAid Medical Ltd. developed a smartphone-based tele stroke system named CVA-Flow. This system aims to evaluate the patient's neurological status, particularly detection of a possible stroke, assessment of stroke severity, and prediction of LVO as the cause of stroke. The system's app guides the user through the examination step by step based on NIHSS/ Rapid Arterial Occlusion Evaluation (RACE) scales. The video can also be transferred offline to enable a distant stroke physician to assess the patient's status manually.

Condition or Disease Intervention/Treatment Phase
  • Device: CVA-Flow

Detailed Description

Management of acute ischemic stroke has changed dramatically following the evidence of the superiority of endovascular treatment (EVT) over best medical management, in the treatment of patients suffering large vessel occlusion (LVO), within 24 hours from onset of symptoms. The immediate consequence was an increase in the number of patients eligible for EVT, requiring secondary transfer of those patients from primary stroke centers to comprehensive stroke centers, capable of performing EVT.

EVT requires accurate and rapid diagnosis in the prehospital setting, as it is only indicated in specific patients with LVO, making up a small percentage of stroke cases, and its beneficial effects are highly time-dependent.

Of the existing diagnostic tools that accurately distinguish LVO cases from non-LVO ones, the National Institutes of Health Stroke Scale (NIHSS) is the most recommended tool by healthcare providers to objectively quantify the neurological impairment caused by a suspected stroke. Nevertheless, the NIHSS is not considered to be feasible in the pre-hospital setting of EMS, since it requires a greater degree of training, is thought to be too time-consuming, and has not been as well validated in the prehospital setting.

Several previous studies showed feasibility and reliability of the use of telemedicine for determining the NIHSS score from afar in stroke patients in real time, in simulated stroke patients in real time and captured video segments. Previous studies did not use designated applications designed for performing neurological evaluations, relying on simple applications for video conferencing instead, therefore requiring applicators to possess knowledge in performing neurological examinations and evaluators to be online the whole examination time.

To resolve this issue, CVAid Medical Ltd. developed a smartphone-based tele stroke system named CVA-Flow. This system aims to evaluate the patient's neurological status, particularly detection of a possible stroke, assessment of stroke severity, and prediction of LVO as the cause of stroke. The system's app guides the user through the examination step by step based on NIHSS/ Rapid Arterial Occlusion Evaluation (RACE) scales. The video can also be transferred offline to enable a distant stroke physician to assess the patient's status manually.

Study Design

Study Type:
Observational
Anticipated Enrollment :
460 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Multi-center, Non-interventional Prospective Clinical Trial to Evaluate the Safety and Effectiveness of CVA-FLOW Software Device for the Detection of Stroke and LVO in Patients With Suspected Stroke
Anticipated Study Start Date :
Oct 23, 2023
Anticipated Primary Completion Date :
May 30, 2024
Anticipated Study Completion Date :
May 30, 2024

Outcome Measures

Primary Outcome Measures

  1. Co-primary endpoints are defined to demonstrate the performance of CVA-Flow to detect patients with stroke among all suspected patients. [From the time of recruitment of the subject to discharge from hospital estimated to be up to 4 weeks]

    The co-primary endpoints are defined as follows, Reference for each case shall be scored by the reviewer neurologist dichotomously as: Positive - at least one relevant finding, or; Negative - no relevant findings. Each case shall also be scored dichotomously by CVA-Flow software as: Positive - suspected stroke, or; Negative - no suspected stroke.

Secondary Outcome Measures

  1. Confirmatory secondary endpoints are defined to demonstrate the performance of CVA-Flow to detect patients with LVO stroke among all suspected patients without head bleeding. [From the time of recruitment of the subject to discharge from hospital estimated to be up to 4 weeks]

    The confirmatory secondary endpoints are defined similarly to the co-primary endpoints as follows, Reference for each case shall be scored by the reviewer radiologist dichotomously as: Positive - at least one relevant finding (LVO), or; Negative - no relevant findings. Each case shall also be scored dichotomously by CVA-Flow software as: Positive - suspected LVO, or; Negative - no suspected relevant findings.

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age ≥21 years of age

  • With suspected acute stroke at the ED prior to treatment (tPA or EVT)

Exclusion Criteria:
  • Patient intubated upon arrival

  • Patient treated with tPA prior to arrival at the ED

  • Patients with the following conditions:

  • Brain tumors

  • Hypoglycemia

  • Toxic poisoning

  • Seizures

  • Sepsis

  • Subdural hematoma

  • Encephalopathy (uremic, hepatic or other)

  • Encephalitis

  • Previous stroke with permanent neurological deficit

Contacts and Locations

Locations

Site City State Country Postal Code
1 Icahn School of Medicine at Mount Sinai New York New York United States 10029
2 Hospital Vall d'Hebron - Neurology Barcelona Spain 08035

Sponsors and Collaborators

  • Cvaid Medical
  • Donawa Lifescience Consulting

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Cvaid Medical
ClinicalTrials.gov Identifier:
NCT06101004
Other Study ID Numbers:
  • CVA-001
First Posted:
Oct 25, 2023
Last Update Posted:
Oct 25, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Cvaid Medical
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 25, 2023